Oppenheimer Healthcare is Staying Active into 2022
- February 7, 2022
Oppenheimer Healthcare: A Trusted Partner in Turbulent Times
With a long tenure in the business, the Oppenheimer team has helped companies like yours with creative and actionable advice throughout multiple market cycles. We specialize in providing deal certainty even during turbulent times so companies can get back to their primary goal of building value by providing patients with new therapeutic options.
Our diverse backgrounds including banking, operational, scientific and financial experience make us uniquely qualified to understand and support your business.
Please contact us to discuss how the Oppenheimer team can help you achieve your capital markets goals.
Michael A. Margolis, R.Ph.Title:
Co-Head of Healthcare, Head of Healthcare Life Sciences
This document is for discussion purposes only and does not constitute advice of any kind, including tax, accounting, legal or regulatory advice, and Oppenheimer & co. Inc. Is not and does not hold itself out to be an advisor as to tax, accounting, legal or regulatory matters.
The information contained herein was obtained from public sources and was relied upon by Oppenheimer & co. Inc. Without assuming responsibility for independent verification as to the accuracy or completeness of such information. No representation or warranty, express or implied, is made as to the accuracy or completeness of such information and nothing contained herein is, or shall be relied upon as, a representation or warranty, whether as to the past or the future.
Oppenheimer & co. Inc. assumes no obligation to update or otherwise revise these materials.
Oppenheimer & co. Inc.’s research department is required to be independent from its investment banking department, and its research analysts may hold and make statements or investment recommendations that differ from the views of its investment bankers. Further, pursuant to applicable law, Oppenheimer & co. Inc. Is (among other things) precluded from offering favorable research, a specific rating or a specific price target, or threaten to change research, a rating or a price target, as consideration or inducement for the receipt of business or compensation.
Oppenheimer & co. Inc. Transacts business on all principal exchanges and member SIPC